HAART Adverse Events

Medical Advocates
HAART/ART

Adverse Events

HAART Main Page

Main New/Newsworthy

Home Page

Last Update: December 31, 2011
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General/Miscellaneous Reports

Journal Papers, Abstracts, and Commentaries

Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs:
Clinical Implications.
Blas-Garcia A, Apostolova N, Esplugues JV.
Curr Pharm Des. 2011 Dec 1;17(36):4076-86..
Abstract

Long term complications in patients with poor immunological recovery despite virological successful
HAART in Dutch ATHENA cohort.
Van Lelyveld SF, Gras L, Kesselring A, et al
AIDS. 2011 Nov 22.
Abstract

A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS
or Death After HAART Among HIV-Infected Men.
Desquilbet L, Jacobson LP, Fried LP
J Gerontol A Biol Sci Med Sci. 2011 Jun 30
Abstract

Common Adverse Effects of Antiretroviral Therapy for HIV Disease.
Reust CE.
Am Fam Physician. 2011 Jun 15;83(12):1443-51
Abstract

Additive Effects of Numbness and Muscle Aches on Fatigue Occurrence in Individuals with HIV/AIDS
Who Are Taking Antiretroviral Therapy.
Wantland DJ, Mullan JP, Holzemer WL, et al J
Pain Symptom Manage. 2011 Jan 12.
Abstract

FULL-TEXT ARTICLE
Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in
HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy.
Bellistrì GM, Casabianca A, Merlini E, et al
PLoS One. 2010 Dec 31;5(12):e15663
Paper

Taking Side-Effects into Account for HIV Medication.
Costanza V, Rivadeneira P, Biafore F, D'Attellis C.
IEEE Trans Biomed Eng. 2010 May 24
Abstract

Clinical and Demographic Variables Related to Pain in HIV-Infected Individuals
Treated with Effective, Combination Antiretroviral Therapy (cART).
Cervia LD, McGowan JP, Weseley AJ
Pain Med. 2010 Mar 4.
Abstract

Effect of combination antiretroviral treatment on total protein and calculated globulin
levels among HIV-infected patients.
Serpa J, Haque D, Valayam J, et al
Int J Infect Dis. 2010 Feb 3.
Abstract

Understanding and Managing the Adverse Effects of Antiretroviral Therapy.
Hawkins T.
Antiviral Res. 2009 Oct 23.
Abstract

Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving
HAART.
Belaunzarán PF, García-León ML, Wong-Chew RM, et al
Vaccine. 2009 Sep 29.
Abstract

Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy:
systematic review.
Chowers MY, Gottesman BS, Leibovici L, et al
J Antimicrob Chemother. 2009 May 28.
Abstract

A new era of antiretroviral drug toxicity.
Calmy A, Hirschel B, Cooper DA, Carr A.
Antivir Ther. 2009;14(2):165-79.
Abstract

HIV epidemiology and the effects of antiviral therapy on long-term consequences.
Quinn TC
AIDS. 2008 Sep;22 Suppl 3:S7-12.
Abstract

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
Baker JV, Peng G, Rapkin J, et al
AIDS. 2008 Apr 23;22(7):841-8.
Abstract

Ethnicity, Race, and Gender: Differences in Serious Adverse Events Among Participants in an
Antiretroviral Initiation Trial: Results of CPCRA 058 (FIRST Study).
Tedaldi EM , Absalon J, Thomas AJ , et al
JAIDS 47(4):441-448, April 1, 2008.
Abstract

Syncope as a probable side effect to combination antiretroviral therapy initiated during primary
HIV-1 infection.
Lybaek D, Larsen CS.
Sex Health. 2008 Mar;5(1):69-71.
Abstract

Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life
in HIV-Infected Individuals.
Mannheimer SB, Wold N, Gardner EM, et al
Clin Infect Dis. 2008 Feb 15
Abstract

Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and
treatment modification.
Keiser O, Fellay J, Opravil M, et al.
Antivir Ther. 2007;12(8):1157-64.
Abstract

Ethnicity, Race, and Gender: Differences in Serious Adverse Events Among Participants
in an Antiretroviral Initiation Trial: Results of CPCRA 058 (FIRST Study).
Tedaldi EM, Absalon J, Thomas AJ, et al
J Acquir Immune Defic Syndr. 2007 Dec 20
Abstract

Side effects of HIV therapy.
Esser S, Helbig D, Hillen U, et al
J Dtsch Dermatol Ges. 2007 Sep;5(9):745-754.
Abstract

FULL TEXT PDF ARTICLE
Complications of HIV Disease and Therapy.
Currier JS, Havlir DV.
Top HIV Med. 2007 Apr-May;15(2):40-7.
Paper

Coping with HIV Treatment Side Effects: Conceptualization, Measurement, and Linkages.
Johnson MO, Neilands TB.
AIDS Behav. 2007 Apr 11;
Abstract

Immune Reconstitution Inflammatory Syndrome Presenting as Sinusitis with Inflammatory
Pseudotumor in an HIV-Infected Patient: A Case Report and Review of the Literature.
Chan-Tack KM, Chengappa KS, Wolf JS, et al
AIDS Patient Care STDS. 2006 Dec;20(12):823-8.
Abstract

Impact of Antiretroviral Treatment-Related Toxicities on Hospital Admissions in HIV-Infected
Patients.[Spain}
Nunez MJ, Martin-Carbonero L, Moreno V, et al
AIDS Res Hum Retroviruses. 2006 Sep;22(9):825-9
Abstract

Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.
Boulassel MR, Morales R, Murphy T, et al
J Med Virol. 2006 Jul 17;78(9):1158-1163
Abstract

High incidence of adverse reactions to initial antiretroviral therapy in Brazil.
Menezes de Padua CA, Cesar CC, et al
Braz J Med Biol Res. 2006 Apr;39(4):495-505.
Abstract

Antiretroviral therapy affects the composition of weight loss in HIV infection: Implications
or clinical nutrition.
Maia BS, Engelson ES, Wang J, Kotler DP.
Clin Nutr. 2005 Aug 9;
Abstract

Identification, management, and prevention of adverse effects associated with
highly active antiretroviral therapy.
Schiller DS.
Am J Health Syst Pharm. 2004 Dec 1;61(23):2507-22.
Abstract

Frequent Reactivation of Herpes Simplex Virus among HIV-1-Infected
Patients Treated with Highly Active Antiretroviral Therapy.
Posavad CM, Wald A, Kuntz S, et al
J Infect Dis. 2004 Aug 15;190(4):693-6.
Abstract

FULL-TEXT PDF ARTICLE
Complications of Antiretroviral Therapies and HIV
Keruly JK
The Hopkins HIV Report, March 2004 Vol 16. No 2
Paper

Adverse effects of antiretroviral therapy for HIV infection.
Montessori V, Press N, Harris M, et al.
CMAJ. 2004 Jan 20; 170(2): 229-38
Abstract

Antiretroviral Therapy-associated Serious and Life-threatening Toxicities.
Pau AK.
Curr Infect Dis Rep. 2003 Oct;5(5):429-438.
Abstract

Conference Reports, Abstracts, and Posters

AIDS-defining Illnesses after Initiating Generic HAART in South India: The Case for Earlier
Identification and Intervention
N Kumarasamy, K Venkatesh, B Devaleenol, et al
(16 CROI)
Abstract

Quantitative and qualitative mtDNA-lesions with mitochondrial dysfunction in multiple organs after
HAART-associated fatal lactacidosis
Thoden J, Lebrecht D, Venhoff N, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract

Evaluation of adherence and toxicities to HAART in a cohort of HIV+ immigrant patients in south-eastern Spain
during the period 1998–2007
Vera-Méndez FJ, Trujillo-Santos J, Cano-Sánchez A, et al
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract

Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive
HAART: resultsfrom the German ClinSurv cohort
Zoufaly A, Kreuzberg C, An der Heiden M, et al |
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract

Is older age a risk factor for antiretroviral toxicities?
C A Sabin, C J Smith, T Hill, et al
(8th Int Congress on Drug Therapy in HIV Infection)
Abstract

Early Clinical Toxicity to Nonnucleoside Reverse Transcriptase Inhibitor-based HAART in a
Home-based AIDS Care Program in Rural Uganda
F Forna, C Liechty, P Solberg, et al
(13 CROI)
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Differences in Adverse Event Profiles in Antiretroviral-Naive Subjects Starting Antiretroviral
Therapy with CD4 Counts <50 Cells/mm³ vs. >200 Cells/mm³:Does Immune Reconstitution
Inflammatory Syndrome (IRIS) Play a Role?
C Fichtenbaum, WC Woodward, T Bykov, et al
(10th EACS)
PDF Poster

Blood Disorders

Hyperbilirubinemia

Journal Papers, Abstracts, and Commentaries

Gilbert syndrome and the development of antiretroviral therapy-associated
hyperbilirubinemia.
Rotger M, Taffe P, Bleiber G, et al
J Infect Dis. 2005 Oct 15;192(8):1381-6.
Abstract

Hypergammaglobulinaemia

Journal Papers, Abstracts, and Commentaries

The effect of combination antiretroviral therapy on CD5 B- cells, B-cell
activation and hypergammaglobulinaemia in HIV-1-infected patients.
Redgrave BE, Stone SF, French MA, et al
HIV Med. 2005 Sep;6(5):307-12
Abstract

Hyperlactemia

Journal Papers, Abstracts, and Commentaries

Leukemia

Journal Papers, Abstracts, and Commentaries

Advanced acute myelogenous leukaemia (AML) during HAART-treated HIV disease,
manifesting initially as a thyroid mass.
Manfredi R, Sabbatani S, Chiodo F. et al
Scand J Infect Dis. 2005 Oct;37(10):781-783.
Abstract

Central/Peripheral Nervous System Disorders

Journal Papers, Abstracts, and Commentaries

Fulminant inflammatory leukoencephalopathy associated with HAART-induced
immune restoration in AIDS-related progressive multifocal leukoencephalopathy.
Vendrely A, Bienvenu B, Gasnault J, et al
Acta Neuropathol (Berl). 2005 Mar 1;
Abstract

Cutaneous and Integumentary System Disorders

General Reports

Journal Papers, Abstracts, and Commentaries

Cutaneous toxicities of antiretroviral therapy for HIV Part I. Lipodystrophy syndrome, nucleoside
reverse transcriptase inhibitors, and protease inhibitors.
Introcaso CE, Hines JM, Kovarik CL.
J Am Acad Dermatol. 2010 Oct;63(4):549-561
Abstract

Cutaneous toxicities of antiretroviral therapy for HIV Part II. Nonnucleoside reverse transcriptase i
nhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome.
Introcaso CE, Hines JM, Kovarik CL.
J Am Acad Dermatol. 2010 Oct;63(4):563-569.
Abstract

Mycoses

Journal Papers, Abstracts, and Commentaries

Increased incidence of cutaneous mycoses after HAART initiation: a benign form of immune
reconstitution disease?
Nacher M, Vantilcke V, Mahamat A, et al
AIDS. 2007 Oct;21(16):2248-2250.
Abstract

Breast Disorders

Breast Abscess

Journal Papers, Abstracts, and Commentaries

Cryptococcal breast abscess in an HIV-positive patient: Arguments for reviewing the definition
of immune reconstitution inflammatory syndrome.
Haddow LJ, Sahid F, Moosa MY.
J Infect. 2008 Feb 26
Abstract

Gynecomastia

Journal Papers, Abstracts, and Commentaries

Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy.
Deonarain J, Ramdial PK, Singh B.
Int J Surg Pathol. 2008 Apr;16(2):171-5.
Abstract

Gynecomastia in HIV-infected patients receiving antiretroviral therapy.
Garcia-Benayas T, Blanco F, Martin-Carbonero L, et al
AIDS Res Hum Retroviruses. 2003 Sep;19(9):739-41
Abstract

Breast enlargement in 13 men who were seropositive for human
immunodeficiency virus.
Evans DL, Pantanowitz L, Dezube BJ, Aboulafia DM.
Clin Infect Dis. 2002 Nov 1;35(9):1113-9
Abstract

Toxiderma

Journal Papers, Abstracts, and Commentaries

Antiretroviral-induced toxiderma in HIV-infected patients
Caumes E, Bossi P, Katlama C, Bricaire F.
Presse Med. 2003 Sep;32(28):1325-1333.
Abstract

Endocrine Disorders

Journal Papers, Abstracts, and Commentaries

Secondary Hyperparathyroidism in HIV patients: is there any responsibility of HAART?
Daria P, Laura C, Elena R, et al
AIDS. 2011 May 25
Abstract

Thyroid function in human immunodeficiency virus patients treated with highly active
antiretroviral therapy (HAART): a longitudinal study.
Madeddu G, Spanu A, Chessa F, et al
Clin Endocrinol (Oxf). 2006 Apr;64(4):375-83.
Abstract

Sexual Dysfunction

Journal Papers, Abstracts, and Commentaries

Sexual dysfunction in the highly active antiretroviral therapy era.
Collazos J.
AIDS Rev. 2007 Oct-Dec;9(4):237-45.
Abstract

Antiretroviral therapy is associated with sexual dysfunction and with increased
serum oestradiol levels in men.
Lamba H, Goldmeier D, Mackie NE, Scullard G.et al
Int J STD AIDS. 2004 Apr;15(4):234-7.
Abstract

Eye Disorders

Journal Papers, Abstracts, and Commentaries

Emergence of multiple drug-resistant human cytomegalovirus variants in 2
patients with human immunodeficiency virus infection unresponsive to
highly active antiretroviral therapy.
Baldanti F,Paolucci S, Parisi A
Clin Infect Dis 2002 Apr 15;34(8):1146-9
Abstract

Conference Reports, Abstracts, and Posters

CMV-Specific CD4+T Lymphocyte Function in Long-Term Survivors of CMV
Retinitis (CMVR) Receiving HAART.
MA Jacobson, R Schrier, JM McCune, et al.
(8 CROI)
Abstract

Mental Health Disorders

Journal Papers, Abstracts, and Commentaries

Psychiatric Risk Factors for HIV Disease Progression: The Role of Inconsistent
Patterns of Antiretroviral Therapy Utilization.
Carrico AW, Riley ED, Johnson MO, et al
J Acquir Immune Defic Syndr. 2010 Nov 24.
Abstract

HIV-1-Associated Dementia During HAART Therapy.
Aquaro S, Svicher V, Ronga L, et al
Recent Patents CNS Drug Discov. 2008 Jan;3(1):23-33.
Abstract

Major depression-related immunological changes and combination antiretroviral therapy in
HIV-seropositive patients.
Alciati A, Gallo L, Monforte AD, et al
Hum Psychopharmacol. 2006 Dec 27;22(1):33-40
Abstract

Neuropsychiatric complications of antiretroviral therapy.
Cespedes MS, Aberg JA. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients:
Effects of Antiretroviral Therapy and Adipose Tissue Distribution.
van Wijk JP, Cabezas MC.
Int J Vasc Med. 2012;2012:201027.
Abstract
Drug Saf. 2006;29(10):865-74.
Abstract

Metabolic Disorders
Metabolic Syndrome

Journal Papers, Abstracts, and Commentaries

FULL-TEXT PDF ARTICLE
Dyslipidemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the
Spanish VACH cohort.
Estrada V, Geijo P, Fuentes-Ferrer M, et al
BMC Womens Health. 2011 Aug 4;11(1):36
Paper

Switching antiretroviral therapy to minimize metabolic complications.
Lake JE, Currier JS.
HIV Ther. 2010 Nov;4(6):693-711
Abstract

Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with
Antiretroviral Therapy in HIV-Infected Patients.
Veloso S, Peraire J, Viladés C, et al
Curr Pharm Des. 2010 Aug 5
Abstract

Lipotoxicity on the Basis of Metabolic Syndrome and Lipodystrophy in HIV-1-Infected
Patients Under Antiretroviral Treatment.
Giralt M, Díaz-Delfín J, Gallego-Escuredo JM, et al
Curr Pharm Des. 2010 Aug 5.
Abstract

Adipose Tissue as a Target of HIV-1 Antiretroviral Drugs. Potential Consequences on
Metabolic Regulations.
Caron-Debarle M, Boccara F, Lagathu C, et al
Curr Pharm Des. 2010 Aug 5
Abstract

Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1
Infected Patients.
Stankov MV, Behrens GM.
Curr Pharm Des. 2010 Aug 5.
Abstract

Drug-induced lipotoxicity: lipodystrophy associated with HIV-1-infection and antiretroviral treatment.
Villarroya F, Domingo P, Giralt M.
Biochim Biophys Acta. 2009 Sep 29.
Abstract

Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV-infected individuals
receiving highly active antiretroviral therapy.
Míguez-Burbano MJ, Lewis JE, Malow R.
J Assoc Nurses AIDS Care. 2009 May-Jun;20(3):176-83
Abstract

Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular
remodeling of the brachial artery in a population of HIV-infected patients.
Rossi R, Nuzzo A, Guaraldi G, Squillace N, et al
Metabolism. 2009 Apr 22.
Abstract

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease
inhibitor-sparing regimens for initial HIV treatment.
Haubrich RH, Riddler SA, Dirienzo AG, et al
AIDS. 2009 May 4.
Abstract

The Effect of Individual Antiretroviral Drugs on Body Composition in HIV-Infected Persons Initiating
Highly Active Antiretroviral Therapy.
Shlay JC, Sharma S, Peng G, et al
J Acquir Immune Defic Syndr. 2009 Apr 29
Abstract

Human Immunodeficiency Virus and Highly Active Antiretroviral Therapy-Associated Metabolic Disorders
and Risk Factors for Cardiovascular Disease.
Anuurad E, Semrad A, Berglund L.
Metab Syndr Relat Disord. 2009 Apr 8.
Abstract

Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive
persons initiating antiretroviral therapy.
Gibert CL, Shlay JC, Sharma S, et al
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):44-53.
Abstract

Metabolic syndrome associated with HIV and highly active antiretroviral therapy.
Barbaro G, Iacobellis G.
Curr Diab Rep. 2009 Feb;9(1):37-42
Abstract

The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular
Mechanisms and Clinical Implications.
Flint OP, Noor MA, Hruz PW, et al
Toxicol Pathol. 2009 Jan 26.
Abstract

Metabolic Abnormalities Associated With HIV Infection and Antiretroviral Therapy.
Fichtenbaum CJ.
Curr Infect Dis Rep. 2009 Jan;11(1):84-92
Abstract

Obesity among Patients with HIV: The Latest Epidemic.
Crum-Cianflone N, Tejidor R, Medina S, et al
AIDS Patient Care STDS. 2008 Dec;22(12):925-30
Abstract

A Prospective Study of Body Fat Redistribution, Lipid, and Glucose Parameters in HIV-Infected Patients
Initiating Combination Antiretroviral Therapy.
Walmsley S, Cheung AM, Fantus G, et al
HIV Clin Trials. 2008 Sep-Oct;9(5):314-23.
Abstract

A WEEK IN REVIEW FEATURED REPORT
Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study.
Tien PC, Schneider MF, Cole SR, et al
J Acquir Immune Defic Syndr. 2008 Oct 16
Abstract

Management of morphologic changes associated with antiretroviral use in HIV-infected patients.
Wohl DA, Brown TT.
J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S93-S100.
Abstract

Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients:
pathogenesis, prevention, and treatment options.
Tebas P
J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S86-92.
Abstract

HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in
HIV-infected patients.
Kotler DP.
J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S79-85.
Abstract

Metabolic side effects of antiretroviral therapy
van der Valk M, Reiss P.
Ned Tijdschr Geneeskd. 2008 May 31;152(22):1260-4.
Abstract

Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the
Spanish VACH Cohort.
Pere D, Ignacio SL, Ramón T,
Open AIDS J. 2008;2:26-38.
Abstract

HIV Therapy, Metabolic Syndrome, and Cardiovascular Risk.
Pao V, Lee GA, Grunfeld C. et al
Curr Atheroscler Rep. 2008 Feb;10(1):61-70
Abstract

Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients:
considerations for psychosocial aspects.
Fernandes AP, Sanches RS, Mill J, et al
Rev Lat Am Enfermagem. 2007 Oct;15(5):1041-1045.
Abstract

Metabolic consequences and therapeutic options in highly active antiretroviral therapy
in human immunodeficiency virus-1 infection.
Samaras K
J Antimicrob Chemother. 2007 Dec 10
Abstract

Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic
complications.
Tarr PE, Telenti A.
Antivir Ther. 2007;12(7):999-1013.
Abstract

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults
exposed to antiretroviral therapy.
Lactic Acidosis International Study Group.
AIDS. 2007 Nov 30;21(18):2455-64.
Abstract

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after
initiation of antiretroviral therapy in HIV infection.
Wand H, Calmy A, Carey DL, Samaras K, et al
AIDS. 2007 Nov 30;21(18):2445-2453.
Abstract

A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly
active antiretroviral therapy in Soweto, South Africa.
Bolhaar MG, Karstaedt AS.
Clin Infect Dis. 2007 Jul 15;45(2):254-60.
Abstract

Antiretroviral Therapies Associated with Lipoatrophy in HIV-Infected Women.
Tien PC, Barron Y, Justman JE, et al
AIDS Patient Care STDS. 2007 May;21(5):297-305
Abstract

Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and
hyperlipidemia.
Araujo PS, Ximenes RA, Lopes CF, et al
Rev Inst Med Trop Sao Paulo. 2007 Apr;49(2):73-78.
Abstract

Toxic metabolic syndrome associated with HAART.
Haugaard SB.
Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):429-45.
Abstract

Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and
cardiovascular risk
Barbaro G.
Am J Ther. 2006 May-Jun;13(3):248-60.
Abstract

Mixed Patterns of Changes in Central and Peripheral Fat Following Initiation of
Antiretroviral Therapy in a Randomized Trial.
Mulligan K, Parker RA, Komarow L
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):590-597
Abstract

Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome and Cardiovascular
Risk.
Barbaro G, Barbarini G.
Chemotherapy. 2006 May 2;52(4):161-165
Abstract|

Changes in Weight and Lean Body Mass during Highly Active Antiretroviral
Therapy.
Shikuma CM, Zackin R, Sattler F, et al
Clin Infect Dis. 2004 Oct 15;39(8):1223-30
Abstract

Conference Reports, Abstracts, and Posters
	POSTER ART Exposure and Insulin Resistance in the Women’s Interagency HIV Study P Tien, M Schneide, S Cole, et al (15 CROI) PDF Poster Abstract

Mitochondrial Disorders

Journal Papers, Abstracts, and Commentaries

Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy
and not to HIV infection.
McComsey GA, Libutti DE, O'Riordan M, et al
Antivir Ther. 2008;13(5):715-22.
Abstract

HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive
oxygen species production, but not apoptosis.
Jiang B, Hebert VY, Li Y, Mathis J
Abstract

Antiretroviral therapy and mitochondrial toxicity.
Santos Corraliza E, Fuertes Martin A.
Med Clin (Barc). 2007 Mar 3;128(8):311-6.
Abstract

Anti-HIV drugs and the mitochondria.
Pinti M, Salomoni P, Cossarizza A. et al
Biochim Biophys Acta. 2006 May 11;
Abstract

Mitochondrial Effects of HIV Infection on the Peripheral Blood Mononuclear
Cells of HIV-Infected Patients Who Were Never Treated with Antiretrovirals.
Miro O, Lopez S, Martinez E, et al
Clin Infect Dis. 2004 Sep 1;39(5):710-6
Abstract

Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management.
McComsey G, Lonergan JT.
J Acquir Immune Defic Syndr. 2004 Sep 1;37:S30-S35.
Abstract

Prospective evaluation of blood concentration of mitochondrial DNA as a marker
of toxicity in 157 consecutively recruited untreated or HAA
Lab Invest. 2004 May 3
Abstract

Mitochondrial toxicity associated with HAART following liver transplantation
in an HIV-it.
Antoniades C, Macdonald C, Knisely A, et al
Liver Transpl. 2004 May;10(5):699-702
Abstract

Mitochondrial toxicity in the era of HAART: evaluating venous lactate and
peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral
therapy.
Montaner JS, Cote HC, Harris M, et al
J Acquir Immune Defic Syndr. 2003 Sep;34
Abstract

Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient
affected by lactic acidosis after treatment with highly active antiretroviral therapy.
Tolomeo M, Mancuso S, Todaro M, et al.
J Clin Pathol 2003 Feb;56(2):147-51
Abstract

Mitochondrial proliferation, DNA depletion and adipocyte differentiation in
subcutaneous adipose tissue of HIV-positive HAART recipients.
Pace CS, Martin AM, Hammond EL
Antivir Ther. 2003 Aug;8(4):323-31.
Abstract

Mitochondrial damage associated with long-term antiretroviral treatment:
associated alteration or causal disorder?
Vittecoq D, Jardel C, Barthelemy C, et al.
J Acquir Immune Defic Syndr 2002 Nov 1;31(3):299-308
Abstract

Central and Peripheral Nervous Systems

Journal Papers, Abstracts, and Commentaries

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term.
McPhail ME, Robertson KR.
Curr HIV/AIDS Rep. 2011 Aug 12
Abstract

Brain dysfunction in the era of combination antiretroviral therapy: Implications
for the treatment of the aging population of HIV-infected individuals.
Clark US, Cohen RA.
Curr Opin Investig Drugs. 2010 Aug;11(8):884-900
Abstract

Incident Neuropathy in HIV-Infected Patients on HAART.
Nakamoto BK, McMurtray A, Davis J, et al
AIDS Res Hum Retroviruses. 2010 Jul 12
Abstract

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with
Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy.
Canestri A, Lescure FX, Jaureguiberry S, et al
Clin Infect Dis. 2010 Jan 25.
Abstract

Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral
therapy.
Cardenas V, Meyerhoff D, Studholme C, et al
J Neurovirol. 2009 Jun 4:1-10.
Abstract

HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C
virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of
liver biopsy.
Pascual-Pareja JF, Caminoa A, Larrauri C, et al
AIDS. 2009 May 15;23(8):971-5
Abstract

Cerebrovascular Ischemic Events in HIV-1-Infected Patients Receiving Highly Active Antiretroviral
Therapy: Incidence and Risk Factors.
Corral I, Quereda C, Moreno A, et al
Cerebrovasc Dis. 2009 Apr 24;27(6):559-563.
Abstract

Motor function and human immunodeficiency virus-associated cognitive impairment in a highly
active antiretroviral therapy-era cohort.
Robinson-Papp J, Byrd D, Mindt MR, et al
Arch Neurol. 2008 Aug;65(8):1096-101.
Abstract

Otoneurological manifestations associated with antiretroviral therapy.
Vieira AB, Greco DB, Teófilo MM, Gonçalves DU.
Rev Soc Bras Med Trop. 2008 Jan-Feb;41(1):65-9.
Abstract

Management of advanced HIV disease: resistance, antiretroviral brain penetration and
malignancies.
Boffito M, Pillay D, Wilkins E.
IntJ Clin Pract. 2006 Sep;60(9):1098-106.
Abstract

Oxidant Stress and Peripheral Neuropathy During Antiretroviral Therapy: An AIDS Clinical Trials
roup Study.
Hulgan T, Hughes M, Sun X, et al
J Acquir Immune Defic Syndr. 2006 Jun 19
Abstract

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy:
an adult AIDS clinical trials group study.
Hulgan T, Haas DW, Haines JL, et al
AIDS. 2005 Sep 2;19(13):1341-1349.
Abstract

Conference Reports, Abstracts, and Posters

High rates of asymptomatic neurocognitive impairment (aNCI) in HIV-1 infected subjects receiving
stable combination anti-retroviral therapy (CART) with undetectable plasma HIV RNA
L. Garvey, D. Yerrakalva, A. Winston, et al
(5th IAS Conference)
Abstract

Neurotoxic effect of antiretroviral agents on CNS
Husstedt IW, Reichelt D, Oelker-Grueneberg U, Evers
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract

Oral Disorders

Journal Papers, Abstracts, and Commentaries

Antiretroviral Drug-Associated Oral Lichenoid Reaction in HIV Patient:
A Case Report.
Arirachakaran P, Hanvanich M, Kuysakorn P, Thongprasom K.
Int J Dent. 2010;2010:291072
Abstract

Effects of long-term use of HAART on oral health status of HIV-infected subjects.
Nittayananta W, Talungchit S, Jaruratanasirikul S, et al
J Oral Pathol Med. 2010 Feb 22.
Abstract

The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS).
Navazesh M, Mulligan R, Pogoda J, et al
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Dec;100(6):701-8.
Abstract

The Impact of Highly Active Antiretroviral Therapy and Immunodeficiency on Human
Papillomavirus Infection of the Oral Cavity of Human Immunodeficiency Virus-Seropositive Adults.
Cameron JE, Mercante D, O'brien M, et al
Sex Transm Dis. 2005 Nov;32(11):703-709
Abstract

O ral white patches in a national sample of medical HIV patients in the era
of HAART.
Marcus M, Maida CA, Freed JR, et al
Community Dent Oral Epidemiol. 2005 Apr;33(2):99-106.
Abstract

Conference Reports, Abstracts, and Posters
	Oral lesions as clinical markers of HAART failure: a nested case-control study in Mexico City Ramírez-Amador V., Anaya- Saavedra G, Crabtree-Ramírez B, et al (4th IAS Conference) Abstract

Pancreatic Disorders

Journal Papers, Abstracts, and Commentaries
	The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. Smith CJ, Olsen CH, Mocroft A, et al AIDS. 2008 Jan 2;22(1):47-56. Abstract

Conference Reports, Abstracts, and Posters

Pancreatic toxicity revisited in the HAART era
R Manfredi, L Calza
(8th Int Congress on Drug Therapy in HIV Infection)
Abstract

Risk of Acute Pancreatitis among HIV-infected Patients Who Developed
Marked Hypertriglyceridemia after Receiving Antiretroviral Therapy
C-C Hung, M-Y Chen, W-H Sheng, et al.
(11 CROI)
Abstract

Autoimmune Disease

Graves' Disease

Journal Papers, Abstracts, and Commentaries

	Graves' disease during immune reconstitution in HIV-infected patients treated with HAART. Vos F, Pieters G, Keuter M, van der Ven A. Scand J Infect Dis. 2006;38(2):124-6. Abstract

	Graves' Disease During Immune Reconstitution After Highly Active Antiretroviral Therapy for HIV Infection: Evidence of Thymic Dysfunction French MA AIDS Research and Human Retroviruses Feb 2004, Vol. 20, No. 2: 157-162 Abstract

Gastrointestinal Disorders

Journal Papers, Abstracts, and Commentaries
	Dyspepsia in HIV-infected patients under highly active antiretroviral therapy. Werneck-Silva AL, Prado IB J Gastroenterol Hepatol. 2007 Jun 7; Abstract

Conference Reports, Abstracts, and Posters

POSTER
Gastrointestinal Complaints and use of Acid Reducing Agents are frequent in patients treated
with Antiretrovirals
E Toma , N Ackad , S Auger , J Sampalis
(8th Int Congress on Drug Therapy in HIV Infection)
PDF Poster Abstract

Genitourinary Disorders

General Miscellaneous Disorders

Journal Papers, Abstracts, and Commentaries

Effects of antiretroviral therapy on semen quality.
van Leeuwen E, Wit FW, Repping S, et al
AIDS. 2008 Mar 12;22(5):637-42.
Abstract

Bladder carcinoma and HIV infection during the highly active antiretroviral therapy era:
A rare, but intriguing association. Two case reports and literature review.
Manfredi R, Sabbatani S, Calza L, Chiodo F.
Scand J Infect Dis. 2006 Jul;38(6):566-570.
Abstract

Renal Disorders

Journal Papers, Abstracts, and Commentaries

Nephrotoxicity of HAART.
Kalyesubula R, Perazella MA.
AIDS Res Treat. 2011;2011.
Abstract

Presentation of HIV-associated nephropathy and outcome in HAART-treated patients.
Bigé N, Lanternier F, Viard JP, Kamgang P, et al
Nephrol Dial Transplant. 2011 Jul
Abstract

Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Dauchy FA, Lawson-Ayayi S, de La Faille R, et al
Kidney Int. 2011 May 4. .
Abstract

Renal Disease Associated with Antiretroviral Therapy in the Treatment of HIV.
Cooper RD, Tonelli M.
Nephron Clin Pract. 2011 Jan 4;118(3):c263-c269
Abstract

The Impact of Kidney Function at Highly Active Antiretroviral Therapy Initiation on Mortality in
HIV-Infected Women.
Estrella MM, Parekh RS, Abraham A, et al
J Acquir Immune Defic Syndr. 2010 Jun 25
Abstract

Antiretroviral medications: adverse effects on the kidney.
Jao J, Wyatt CM.
Adv Chronic Kidney Dis. 2010 Jan;17(1):72-82.
Abstract

Subclinical Tubular Injury in HIV-Infected Individuals on Antiretroviral Therapy:
A Cross-sectional Analysis.
Hall AM, Edwards SG, Lapsley M, et al
Am J Kidney Dis. 2009 Sep 22
Abstract

Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients.
Harris M.
Expert Opin Drug Saf. 2008 Jul;7(4):389-400.
Abstract

Nephrotoxicity as a complication of antiretroviral therapy.
Valle R, Haragsim L.
Adv Chronic Kidney Dis. 2006 Jul;13(3):314-9.
Abstract

HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy.
Roling J, Schmid H, Fischereder M,et al
Clin Infect Dis. 2006 May 15;42(10):1488-95.
Abstract

Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.
Wyatt CM, Klotman PE.
Expert Opin Drug Saf. 2006 Mar;5(2):275-287
Abstract

The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons:
results from a randomized trial.
Gupta SK, Parker RA, Robbins GK, Dube MP
Nephrol Dial Transplant. 2005 Aug 16;
Abstract

HAART-related nephropathies in HIV-infected patients.
Daugas E, Rougier JP, Hill G.
Kidney Int. 2005 Feb;67(2):393-403.
Abstract

Resolution of renal failure after initiation of HAART: 3 cases and a discussion of
the literature.
Kirchner JT.
AIDS Read 2002
Abstract

Conference Reports, Abstracts, and Posters

Influence of liver fibrosis on highly active antiretroviral therapy–associated hepatotoxicity
in HIV positive patients
Marino N, Lo Caputo S, Blè C, et al
(4th IAS Conference)
Abstract

Prevalence of renal failure in a HAART cohort in Cambodia and its effect on the occurrence
of NRTI-related side effects
Thay S, An S, Koole O, et al
(4th IAS Conference)
Abstract

Respiratory

Journal Papers, Abstracts, and Commentaries

Overcoming resistance to existing therapies in HIV-infected patients: The role of new
antiretroviral drugs.
Perno CF, Moyle G, Tsoukas C, et al
J Med Virol. 2008 Feb 22;80(4):565-576
Abstract

Sexual Dysfunction

Journal Papers, Abstracts, and Commentaries

Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and
lipodystrophy.
Guaroldi G, Luzi K, Murri R, et al
Antivir Ther. 2007;12(7):1059-65.
Abstract

HAART Main Page

Main New/Newsworthy

Home Page

HAART/ART Adverse Events